FDA Approves Novartis' Fabhalta for IgAN

On August 8, 2024, the FDA officially approved Fabhalta (iptacopan), a groundbreaking drug developed by Novartis Pharmaceuticals for the treatment of immunoglobulin A kidney disease (IgAN). This disease, although rare, is prevalent and affects kidney function by causing an abnormal immune response that attacks kidney tissues, leading to inflammation and proteinuria. Before this approval, Fabatan was recognized in December 2023 for treating the rare condition paroxysmal nocturnal hemoglobinuria (PNH). The latest approval underscores Novartis’s significant contributions to pharmaceutical innovation.

Fabhalta is the first complement inhibitor specifically designed for adults with primary IgA nephropathy. IgAN is a stealthy yet harmful condition where the immune system erroneously targets kidney tissues, causing glomerulitis and proteinuria. Existing treatments have only managed to alleviate the symptoms to some degree, but nearly half of the patients still progress to kidney failure within 10 to 20 years, necessitating dialysis or transplantation.

The Phase III APPLAUSE IgAN clinical trial led by Novartis showcased Fabhalta’s remarkable efficacy. The drug significantly reduced patients' urinary protein-creatinine ratio (UPCR) by 44% over just nine months, outperforming the placebo in both clinical and statistical terms (p<0.0001). Fabhalta’s effectiveness was consistent across various demographics and baseline disease characteristics, highlighting its broad applicability and potential as a standard treatment option.

The unique mechanism of Fabhalta plays a crucial role in its success. By selectively inhibiting the alternative pathway of the complement system, it disrupts a key step in the pathological process of IgAN. This approval not only marks a significant advancement for Novartis in kidney disease treatment but also opens up future possibilities for the company’s kidney disease treatment portfolio. Besides Fabhalta, Novartis is developing other innovative therapies for IgAN, such as atrasentan and zigakibart, to offer patients a wider array of treatment options.

Fabhalta’s application extends beyond IgAN. The drug is also being explored for other rare complement-mediated diseases, including C3 glomerulonephritis (C3G), atypical hemolytic uremic syndrome (aHUS), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and lupus nephritis (LN), showcasing its potential as a versatile treatment.

For many IgAN patients, Fabhalta’s approval brings newfound hope, offering a novel treatment option that promises to improve clinical outcomes and quality of life. Novartis is working to ensure the drug’s accessibility and affordability through partnerships with healthcare providers. Additionally, the company is committed to raising awareness and acceptance of Fabhalta among patients and healthcare professionals to gradually replace older treatments like glucocorticoids, which have significant long-term side effects.

Regarding pricing, Novartis has decided to maintain Fabatan's listing price at $550,000. Though this is higher than the wholesale cost of approximately $120,000 for Filspari, Novartis U.S. President Victor Burto emphasized that the pricing reflects the drug’s potential indications and impact across different disease groups. He asserted that Fabatan's unique value and substantial patient benefits justify its price.

Furthermore, Fabatan offers notable advantages in medication convenience. Unlike Filspari, patients on Fabatan can continue taking regular medications such as angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-II receptor antagonists (ARBs) without needing regular liver function monitoring. Novartis suggests that Fabatan, with its distinct drug mechanism and favorable safety profile, might be better suited for certain types of IgAN patients.

Looking ahead, Novartis will continue to focus on developing and marketing innovative treatments for rare kidney diseases. Through collaborations with medical and research institutions and patient organizations worldwide, the company aims to advance kidney disease treatment and bring new therapies to patients in need.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!